**Supplementary Table 1. Results of time-dependent co-variate and landmark analyses at time-points 3 and 6 months of the trial**

|  |  |  |
| --- | --- | --- |
|  | **Hazard ratio (95% CI)** | **p-value** |
| **Univariate analysis** |  |  |
| **Activated 41BB+ CD8+ T-cells** |  |  |
| Time dependent covariate | 0.98 (0.84; 1.14) | 0.8 |
| Landmarking at 3 months | 1.05 (0.92; 1.19) | 0.5 |
| Landmarking at 6 months | 1.13 (0.96; 1.35) | 0.2 |
| **T-regulatory (CD4+) cells** |  |  |
| Time dependent covariate | 0.99 (0.73; 1.33) | >0.9 |
| Landmarking at 3 months | 1.28 (1.12; 1.47) | <0.001 |
| Landmarking at 6 months | 1.29 (0.88; 1.89) | 0.2 |
| Multivariate analysis |  |  |
| **Time-dependent co-variate analysis**  |  |  |
| Age | 0.92 (0.68; 1.25) | 0.6 |
| 41BB+ CD8+ T-cells | 0.97 (0.82; 1.14) | 0.7 |
| T-regulatory (CD4+) cells | 0.99 (0.74; 1.32) | >0.9 |